Monograph

A10BK03 - Empagliflozin

Propably not porphyrinogenic

Side effects

Genital and urinary tract infections are common side effects of empagliflozin that might potentially be porphyrinogenic.

Rationale

Empagliflozin is not an inducer or an inhibitor of CYP enzymes and is therefore probably not porphyrinogenic.

Chemical description

Empagliflozin is a selective and reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2).

Therapeutic characteristics

Empagliflozin is an anti-diabetic indicated in adults with type 2 diabetes mellitus to improve glycaemic control. It is administered orally.

Metabolism and pharmacokinetics

In vitro data suggest that the primary route of metabolism of empagliflozin in humans is glucuronidation by the uridine 5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, and UGT1A9. Empagliflozin does not inhibit, inactivate, or induce CYP450 (FDA drug label). Interaction studies has not shown any potential for empagliflozin to affect the CYP metabolism of other drugs (Macha 2013a,b)

References

#	Citation details	PMID
*	Scientific articles
1.	Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab. 2013a Apr;15(4):316-23. Macha S, Rose P, et al.
2.	Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther. 2013b Mar;35(3):226-35. Macha S, Sennewald R, et al.	23497760
*	Government bodies
3.	U.S. Food and Drug Administration (FDA). Label information. Jardiance. (Revised: December. 2015).
*	Summary of Product Characteristics
4.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Jardiance.

Citation details

PMID

Scientific articles

Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab. 2013a Apr;15(4):316-23.

Macha S, Rose P, et al.

Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther. 2013b Mar;35(3):226-35.

Macha S, Sennewald R, et al.

23497760

Government bodies

U.S. Food and Drug Administration (FDA). Label information. Jardiance. (Revised:

December. 2015).

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Jardiance.

Similar drugs

Explore alternative drugs in similar therapeutic classes A10B / A10BK or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands

Glusod · Glusod 10 mg filmomhulde tabletten · Glusod 25 mg filmomhulde tabletten · Jardiance · Jardiance 10 mg filmomhulde tabletten · Jardiance 25 mg filmomhulde tabletten

United Kingdom